Online platforms, experts say, can shift the burden of vetting unapproved drugs on to patients

The rapid expansion of GLP-1 receptor agonists—drugs originally engineered to manage type 2 diabetes and chronic obesity—has fundamentally altered the landscape of modern medicine. While pharmaceutical giants like Eli Lilly and biotech innovators such as Altimmune conduct rigorous, late-stage clinical trials to determine if these medications can effectively treat substance use disorders, a growing segment of the digital health industry is moving faster than the regulatory process. By prescribing these medications off-label for conditions ranging from alcohol use disorder to cocaine and methamphetamine dependence, telehealth platforms are creating a gray market that shifts the complex burden of clinical vetting onto the patients themselves.

The Emerging Science of GLP-1s in Addiction Medicine

The biological premise for using GLP-1s to treat addiction lies in the brain’s reward circuitry. GLP-1 receptors are found in the mesolimbic dopamine system, a pathway central to the development of cravings and addictive behaviors. By modulating these pathways, scientists hypothesize that GLP-1 agonists may dampen the "high" associated with substance use or reduce the compulsive desire to consume addictive substances.

Eli Lilly is currently at the forefront of this investigation with brenipatide, while startups like Baseline Therapeutics are aggressively pursuing trials involving alcohol, cocaine, and methamphetamine. Altimmune, meanwhile, has reported promising topline results from Phase 2 trials of its candidate, pemvidutide, in alcohol-related applications. Despite this scientific momentum, no GLP-1 medication has yet received FDA approval for the treatment of any addiction-related condition. The last major milestone in the pharmacological treatment of alcohol use disorder occurred nearly two decades ago, creating a massive vacuum that current telehealth providers are eager to fill.

The Rise of Off-Label Telehealth Prescribing

In the last 18 months, several direct-to-consumer telehealth platforms have begun offering GLP-1s to patients presenting with substance use issues. Unlike traditional brick-and-mortar clinics, which operate under strict oversight and institutional ethical boards, these digital platforms often utilize a streamlined "consultation" model. This model allows for the prescription of both branded GLP-1s (such as Wegovy or Zepbound) and compounded versions—the latter of which are produced in facilities that may not always adhere to the same stringent quality controls as major pharmaceutical manufacturing plants.

The practice of "off-label" prescribing is legal in the United States; physicians have the discretion to prescribe FDA-approved medications for uses not specifically listed on the drug’s label. However, the commercialization of this practice by tech-forward companies introduces a new layer of risk. When a patient navigates a digital interface to secure a medication for an unapproved condition, the "vetting" process—traditionally performed by a doctor in an office who considers a patient’s full medical history and substance use profile—is often reduced to a digital survey.

Chronology of the GLP-1 Regulatory Landscape

• 2005: The FDA approves the first GLP-1 receptor agonist, exenatide, for the treatment of type 2 diabetes.
• 2014: The emergence of liraglutide for weight management begins to shift the perception of GLP-1s from strictly metabolic tools to broader systemic regulators.
• 2021-2022: The explosive popularity of semaglutide (Ozempic/Wegovy) creates a global supply chain shortage and triggers a massive increase in off-label prescribing for weight loss.
• 2023: Early academic papers begin to suggest a correlation between GLP-1 use and reduced alcohol consumption, fueling interest in addiction-related clinical trials.
• 2024-2025: Several telehealth platforms incorporate addiction-related queries into their intake processes, offering GLP-1s as a "treatment" for alcohol use disorder without explicit FDA backing for this specific indication.

Data and Market Implications

The current market for GLP-1s is projected to reach $100 billion annually by the end of the decade, according to various Wall Street analysts. This financial incentive is a primary driver behind the push to expand the "indications" for these drugs. However, the safety profile of these drugs, particularly when combined with substances like alcohol or other illicit drugs, remains under-studied in a real-world, unsupervised setting.

Data from existing obesity trials suggest that GLP-1s can cause significant gastrointestinal distress, pancreatitis, and in rare cases, gallbladder issues. When these drugs are introduced into the lives of patients suffering from substance use disorders, the interactions with their primary substance of abuse—and the secondary lifestyle impacts—are largely unknown. For instance, if a patient is using a GLP-1 to manage alcohol cravings, and they continue to consume alcohol, does the drug mask symptoms of liver stress? Or, conversely, does it interact negatively with the psychological medications often used in addiction recovery?

The Burden of Vetting

The fundamental issue identified by medical ethicists is the shift of responsibility. In a standard clinical setting, the provider is responsible for evaluating the risk-to-benefit ratio of an off-label prescription. In the current digital model, the patient is often left to interpret their own reaction to the drug. If a patient experiences a negative side effect, they are frequently forced to navigate a customer support chatbot or an asynchronous messaging system rather than a physician who knows their medical history.

Experts in addiction medicine argue that this is particularly dangerous for a vulnerable population. Substance use disorders are complex, multifaceted diseases that require comprehensive care, including behavioral therapy, social support, and monitoring. Reducing this care to a monthly subscription for a pharmaceutical product ignores the nuance of recovery.

Official Responses and Industry Stance

While the FDA has not issued a blanket ban on the use of GLP-1s for addiction, it has repeatedly cautioned against the use of compounded drugs, noting that they do not undergo the same level of pre-market review for safety, effectiveness, and quality as FDA-approved versions.

Telehealth companies often defend their practices by citing the urgent, unmet need for addiction treatments. They argue that if these drugs can help even a fraction of patients reduce their substance intake, the benefit outweighs the potential risks of off-label use. They characterize their services as a form of "harm reduction," positioning themselves as a bridge for patients who cannot access specialized addiction medicine clinics.

Broader Impact and Future Outlook

The long-term implications of this trend are significant. If the pharmaceutical industry and the telehealth sector continue to move faster than the regulatory apparatus, we may see a rise in adverse event reports that could eventually lead to stricter federal intervention. Furthermore, there is a risk of stigmatizing the science itself; if early, uncontrolled use of GLP-1s leads to negative patient outcomes, it could complicate the path to legitimate, FDA-approved, and insurance-covered treatments for addiction in the future.

The medical community is currently at a crossroads. As companies continue to solicit investment and market their services, the need for transparent, evidence-based data has never been higher. Patients seeking help for addiction are currently being asked to act as their own clinical trial participants, a reality that highlights a significant failure in the current healthcare system’s ability to regulate innovation without stifling progress.

Ultimately, while the promise of GLP-1s for addiction is grounded in legitimate neurobiological science, the current delivery mechanism is fraught with peril. Until large-scale, randomized controlled trials provide the necessary evidence to support these uses, the reliance on digital platforms to "vet" these drugs represents a high-stakes experiment with public health at the center. Patients should exercise extreme caution, ensuring that any use of these powerful medications occurs under the supervision of a licensed physician who is aware of their entire medical history, rather than a platform that may prioritize growth over patient safety.